Inhibrx (INBX) Director Kimberly Manhard Receives 10,000-Option Award

What Happened

• Kimberly Manhard, a director of Inhibrx Biosciences, received an award of 10,000 derivative securities (stock options) on June 3, 2026. The reported acquisition price is $0.00, so there was no cash paid at grant and no immediate realized value reported.

Key Details

• Transaction date: 2026-06-03; filing is an amended Form 4 (restates the Form 4 filed June 4, 2026) correcting the number of options granted.
• Transaction type/code: Award/Grant (derivative securities) — listed as "A" in the filing.
• Price: $0.00 per option (reported acquisition value $0).
• Vesting/exercise: Footnote F1 states the option will be fully exercisable on June 3, 2027, subject to continued service through that date.
• Shares owned after transaction: Not specified in the provided filing details.
• Timeliness: This filing amends the June 4, 2026 Form 4 to correct the grant amount; no late-filing indication is shown.

Context

• This is a compensation grant (an option award), not an open-market buy or sale. Such awards are common for directors and typically vest over time or contingent on continued service; they do not necessarily indicate immediate insider buying or selling intent. The options are not reported as exercised or sold in this filing.